Associated tags: TELO, MD, Ageing, B cell, Research, Pharmaceutical industry, Longevity, Osteoarthritis, Blood, Chromosome, DNA, Regeneration
Locations: CLEVELAND, BALTIMORE, MD, US, WASHINGTON
Osteoarthritis,
Economics,
TELO,
Hematology,
Animal,
Cleveland Clinic,
Research,
IND,
Weakness,
DRS,
Medicine,
Press club,
Ageing,
Longevity,
Pharmaceutical industry WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.
Key Points:
- As part of its commitment to transparency and openness in sharing its research data, during the event, Drs.
- Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres.
- The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.
- “Our National Press Club event was our first opportunity to share on a national stage Telomir-1’s potential to combat the diseases of aging,” stated Dr. Chapman.
Press club,
B cell,
Longevity,
TELO,
Chromosome,
Research,
DNA,
MD,
Skin,
Osteoarthritis,
Blood,
Ageing,
Pharmaceutical industry BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.
Key Points:
- Dr. Roizen serves as Telomir’s special advisor on age reversal.
- The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
- “Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
- As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.
Diagnosis,
B cell,
Regeneration,
TELO,
Disease,
Research,
Nonsteroidal anti-inflammatory drug,
MD,
Quality of life,
Human,
Osteoarthritis,
FDA,
Ageing BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.
Key Points:
- The study will evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations.
- In addition, Telomir believes that this study could be used as part of its pre-clinicial program for eventually evaluating Telomir-1 in humans.
- It is estimated that nearly 18 million canines in the United States are affected by osteoarthritis.
- “Osteoarthritis is the most common ailment in canines yet there are currently no treatments that combat the disease.
B cell,
Conference,
Longevity,
National University Health System,
TELO,
The New York Times,
BGCT,
Health,
Chromosome,
Research,
DNA,
EDT,
Laboratory,
MD,
Skin,
Poster,
Telomere,
Osteoarthritis,
Blood,
NUHS,
Ageing,
Pharmaceutical industry BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
Key Points:
- The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
- This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
- “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
- To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.
Toxicity,
Notifiable disease,
TELO,
Entrepreneurship,
Science,
Research,
DNA,
Ageing,
MD,
Quality of life,
Drug development,
Osteoarthritis,
Pharmaceutical industry Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.
Key Points:
- Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.
- Additional AI-driven studies now being conducted to demonstrate Telomir-1's promising therapeutic potential, supporting Telomir’s hypothesis with solid computational evidence.
- As part of its work, Telomir works with third-party collaborators Frontage Laboratories and InSilicoTrials, each of whom utilize AI in-silico testing models.
- To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.
Regeneration,
AI,
MD,
Stem cell,
Ageing,
Drug development,
National University Health System,
Telomere,
CHL,
HUVEC,
Conference,
Longevity,
B cell,
NUHS,
MSC,
Poster,
TELO,
Research,
Pharmaceutical industry The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
Key Points:
- The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
- The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
- The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
- To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.
Stem cell,
Advisory board,
Cleveland Clinic,
Regeneration,
Food and Drug Administration,
Blood,
Zinc,
MD,
FDA,
Ageing,
Food,
Cancer,
Overload,
Life,
B cell,
Attention,
Chromosome,
Joint,
Metal,
Heart,
Longevity,
Imagination,
Science,
TELO,
Brain,
Pharmaceutical industry BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.
Key Points:
- A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures.
- He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years.
- Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry.
- We look forward to his continued contributions to our efforts.”
To be included in the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.
Retrieved on:
Tuesday, February 13, 2024
BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share.
Key Points:
- BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share.
- The gross proceeds to Telomir from the initial public offering were $7 million, before deducting underwriting discounts and commissions and other offering expenses.
- Kingswood Investments, a division of Kingswood Capital Partners LLC, acted as sole book-running manager for the initial public offering.
- 333-275534) relating to shares of common stock sold in the initial public offering has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on February 8, 2024.
Retrieved on:
Thursday, February 8, 2024
In addition, Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Key Points:
- In addition, Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
- The gross proceeds to Telomir from the initial public offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $7 million.
- The initial public offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.
- Kingswood Investments, a division of Kingswood Capital Partners LLC., is acting as sole book-running manager for the initial public offering.
